Blogs

Be the first person to recommend this.
Dietary Fiber Intake and Prostate Cancer Outcomes and All-Cause Mortality: Findings From a Secondary Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Study This observational analysis examined how higher dietary fiber intake is associated with the risk of developing prostate cancer, prostate-cancer specific mortality, and all-cause mortality. The authors analyzed data from large screening and follow-up cohorts, comparing men in higher vs lower tertiles of fiber intake. They found that greater fiber consumption was linked with lower incidence of prostate cancer (in certain screening arms) and lower risk of death from all ...
0 comments
Be the first person to recommend this.
Some pretty eye-opening research coming out of Rutgers University et. al. regarding metformin and exercise. No matter the intensity of exercise you're doing, metformin seems to block the benefits people with diabetes should get from exercise. I look forward to more coming out about this. What are your thoughts? Why Your Daily Walk Might Not Work as Well if You're on Metformin Rutgers remove preview Why Your Daily Walk Might Not Work as Well if You're on Metformin A widely-prescribed diabetes drug may be sabotaging one of the most trusted strategies for preventing the disease: exercise. That is the conclusion of ...
0 comments

Menopause and Diabetes

Be the first person to recommend this.
Menopause and Diabetes By: Ramona Hrysikos, MSN Ed, FNP-C, FNP-BC, CDCES, BC-ADM Menopause marks a significant transition in a woman’s life. It can bring a variety of physical and emotional changes. For women already managing diabetes, the onset of menopause can add a layer of complexity to an already demanding health routine and overall health. The hormonal changes during menopause and the significant decline in estrogen and progesterone levels can impact insulin sensitivity. Glucose regulation and metabolism are affected by Estrogen levels. Estrogen has a role in regulating glucose metabolism, and when its levels drop, insulin resistance can ...
0 comments

Sliding Scale Insulin

Be the first person to recommend this.
Sliding Scale Insulin What is sliding scale insulin (SSI)? SSI is a method used to manage blood glucose levels by adjusting the insulin dose based on the patient’s current blood glucose level It is frequently seen in place of prandial insulin in the outpatient setting - when combined with basal insulin, this is referred to as a “sliding scale-basal insulin” regimen Pros & Cons of SSI Pros: Easily adjustable Can be personalized for each patient Cons: Sliding Scale insulin is based on pre-meal glucose levels with no regard to post-meal spike Rather than preventing hyperglycemia, it ...
0 comments
1 person recommends this.
The Thursday before all of the ADCES25 activity, a very important event takes place…………The CB (Community Board)/LNG (Local Networking Group)/COI (Community of Interest) Networking event. It’s an opportunity for members to mingle with other members, introduce themselves to other states, local networking groups and Communities of Interest. Why is this important - we get to connect. Connecting to others is a valuable asset because we learn from others and others learn from you. It’s important to come into the room and start introducing yourself - Don’t be shy, just say HI! Here’s how it works - each state or community of interests will have a table. ...
0 comments
Be the first person to recommend this.
Don’t miss the opportunity to attend the Los Angeles ADCES Diabetes Tech Symposium on June 7th. Join us for the latest updates on therapies and innovative technology that can transform lives. Be part of the future of diabetes management! https://www.adces.org/education/events/unlisted-detail/los-angeles-lng-2025-diabetes-technology-symposium  ͏ ‌ ‌ ...
0 comments
Be the first person to recommend this.
What happens when we stop GLP-1 receptor agonists? Author: Shelley Jeon, PharmD Candidate 2025, Northeastern University School of Pharmacy Reviewer: Courtney Cameron, PharmD, BCACP What data are available on weight regain after stopping GLP-1 receptor agonists? Data from randomized controlled trials suggest that withdrawing either glucagon-like peptide-1 (GLP-1) receptor agonists or dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists leads to a substantial regain of lost weight. The STEP (Semaglutide Treatment Effect in People with obesity) 1 trial was a randomized, placebo-controlled trial ...
0 comments
Be the first person to recommend this.
I had the pleasure of interview Kristen Avera from Open Hand Atlanta to learn more about her program addressing food insecurity with women living with gestational diabetes. The interview recording can be found here: https://youtu.be/9_V04RqDUak or you can read the transcript below! Tell us about yourself. I'm Kristen Avera. I am a registered dietitian. I've been a dietitian for about 10 years. Certified Diabetes Care and Education Specialist for about four years and then in my current organization with Open Hand for about four years as well. So, currently serving as our Nutrition Services manager, we have an awesome group of dietitians throughout our ...
0 comments
1 person recommends this.
Fructosamine Testing for Glycemic Control: When and Why to Order Fructosamine Tests and How to Interpret the Results Author: Emilia Kapcia, PharmD Candidate 2025, Northeastern University School of Pharmacy Reviewer: Courtney Cameron, PharmD, BCACP What are HbA1c and fructosamine tests in diabetes? Diabetes Mellitus (DM) is a chronic condition characterized by high blood glucose. Diabetes causes significant morbidity, disability, and premature mortality through microvascular and macrovascular complications, which can be delayed and even prevented by achieving and maintaining glycemic control. 1 Fructosamine and hemoglobin ...
1 comment
Be the first person to recommend this.
Title: How does the efficacy of Rybelsus compare to DPP4s and SGLT2s in patients with T2DM? Author: Jiwoo Lee, PharmD Candidate 2024, Northeastern University School of Pharmacy Reviewer: Courtney Cameron, PharmD, BCACP What is Rybelsus? Rybelsus (semaglutide) is the first oral GLP-1 RA approved by the FDA to improve glycemic control in patients with T2DM in conjunction with diet and exercise. The medication is available in 3mg, 7mg, and 14mg tablets; the manufacturer recommends initiating with 3mg once daily for 30 days and then escalating to 7mg. The dose can further be increased to 14mg in patients requiring additional ...
0 comments
Be the first person to recommend this.
Stretched Thin On GLP-1/GIP Agonists: Tips for navigating the national shortages By: Bharathi Ravikumar, PharmD and Kaitlyn Craddock, PharmD, BCACP GLP-1 agonists and GLP-1/GIP agonist injectable medications have exploded in popularity across the nation. It seems like everyone from family members to next door neighbors to celebrities are on these medications for weight loss and/or type 2 diabetes treatment. The effectiveness of these medications, once weekly dosing, and ease of administration have made these injections an ideal choice to incorporate into busy lifestyles. With the rise in usage came the subsequent national shortages of these medications. ...
1 comment
1 person recommends this.
Dietary advanced glycation end-products and postmenopausal hot flashes: A post-hoc analysis of a 12-week randomized clinical trial (March 24, 2023) - click for the full study The participants in this study are postmenopausal women aged 40-65 and although living with diabetes was not a requirement of the study, the intervention is promising in reducing hot flashes while supportive of preventive health for women living with diabetes and/or insulin resistance. Objective: Dietary advanced glycation end-products (AGEs) may act as endocrine disruptors, this study examined the potential association of modifications to the intake of dietary AGEs with ...
2 comments
Be the first person to recommend this.
Glucagon-like peptide-1 receptor agonists (GLP-1RA) and Diabetic Retinopathy Prepared by: Emily Short, PharmD, PGY-1 Pharmacy Resident, Boston Medical Center What is diabetic retinopathy? Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus and is one of the most common causes of vision loss worldwide among individuals aged 25 to 74 years. 1 In 2021, the Centers for Disease Control and Prevention (CDC) estimated about 9.6 million people across the United States had been diagnosed with diabetic retinopathy, of which 1.84 million have vision-threatening DR. 2 The development of DR in patients with diabetes occurs ...
0 comments
Be the first person to recommend this.
WV Local Networking Group (LNG) is very excited to have the opportunity have Andrea McCarty, MS, RDN, LD, CDCES speak about patient advocacy related to patients living with diabetes. Andrea is currently employed by WVU as a Certified Diabetes Dietitian at the Pediatric Endocrinology office. Andrea is also involved with the ADCES Advocacy Committee. At the end of the presentation, we will also be discussing with attendees at which location we would want to host our 2024 Diabetes Symposium. WV has not sponsored the Diabetes Symposium since 2016 and we are excited to get it rejuvenated again to provide a support system for the providers providing care for patients ...
0 comments
Be the first person to recommend this.
As the CEO of Umemba Health, Quisha Umemba (pronounced "Kwee-shuh oooMEMbuh") brings over 20 years of diverse experience to her roles as a registered nurse, public health consultant, and entrepreneur. Quisha has developed, implemented, and overseen numerous health initiatives and community collaborations throughout her career. Specializing in Workforce Training and Development, her training approach blends conventional, experiential, and transformational methods to create engaging educational content, delivered across various platforms. Her distinctive approach has earned her the moniker "The Trainer's Trainer." An advocate for health equity, her life's ...
0 comments
1 person recommends this.
The FDA announced November 8, 2023 that it granted approval to Eli Lilly and Co. for Zepbound (tirzepatide) via priority review and fast track designation for chronic weight management (CWM). This is an injectable prescription medicine indicated for CWM in adults with obesity (body mass index (BMI) of at least 30 kg/m2), or with an overweight BMI (at least 27 kg/m2) AND at least one weight related chronic disease/comorbidity, such as diabetes, high blood pressure or high cholesterol. It should be used in conjunction with increased physical activity and a reduced calorie diet. Zepbound (tirzepatide) is administered as a once weekly subcutaneous ...
0 comments
1 person recommends this.
Title: Management of SGLT2i in Patients with Diabetes Preparing for Surgery Author: Vivian Tran, PharmD Candidate 2024, University of Rhode Island School of Pharmacy Reviewer: Courtney Cameron, PharmD, BCACP Background The management of diabetes is often complex, involving a combination of lifestyle changes, pharmacologic therapy, and even surgical interventions. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are recommended for patients with type 2 diabetes and established ASCVD or multiple risk factors for ASCVD. These agents have also shown efficacy and mortality benefit in patients with heart failure and chronic ...
0 comments
1 person recommends this.
By Susannah Chen A newly published study found that type 2 diabetes is not attributed to having obesity as defined by BMI. Rather, each individual’s genetics determine whether or not they have become too heavy for their body and have too much fat inside the pancreas and liver than they can tolerate. The onset of type 2 diabetes is not attributed to having obesity as defined by body mass index (BMI) , a new study has found. It’s actually caused by having more fat inside the liver and pancreas than that particular person can handle. Dr. Roy Taylor, professor of medicine and metabolism at the University of Newcastle School of Medicine in England ...
0 comments
1 person recommends this.
Title : Use of GLP1-RAs in patients with a history of cholelithiasis Author: Sarah Hughes, PharmD Candidate 2024 University of Rhode Island, School of Pharmacy Reviewer: Courtney Cameron, PharmD, BCACP Background Cholelithiasis, also known as gallstones, are hardened collections of bile materials such as cholesterol or bilirubin that collect at the bottom of the gallbladder. The size of a gallstone can vary and most of the time, they do not cause an issue until they get loose and travel into the bile ducts. When a gallstone gets loose it can travel through the bile ducts to the liver or the small intestine causing an obstruction ...
2 comments
Be the first person to recommend this.
This article was published on Diatribe.org in May, 2023. https://diatribe.org/how-to-change-your-attitude-about-diabetes by Lauren Plunkett RDN CDCES Are you feeling angry and fearful about diabetes? There’s a way to channel that negative energy into something productive and motivating. “My blood sugar was great yesterday, but today, I have absolutely had it. I’m all over the place. I’m putting the work in and still, my blood sugars will not stop moving. I am so pissed! ” If this resonates with you, perhaps you’re recalling that voice of criticism inside your head going off about time in range or a high blood glucose spike. If you beat yourself ...
1 comment